[Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].

Abstract

A 79-year-old female with acute promyelocytic leukemia (APL) presented with second hematological relapse. She had been treated previously with modified AIDA protocol as the front-line therapy and had achieved complete remission. During ATRA maintenance therapy, the first hematological relapse occurred and she was treated with arsenic trioxide (ATO), achieving the second complete remission. After four courses of consolidation therapy of ATO, the second hematological relapse occurred. At this time, except for a transient effect of tamibarotene, neither arsenic trioxide nor combination chemotherapy was effective. The patient was then treated with two courses of gemtuzumab ozogamicin (GO) and achieved the third complete remission. At present, she is maintaining molecular remission more than one year after GO treatment. GO is considered to be a promising agent for elderly patients with relapsed acute promyelocytic leukemia resistant to arsenic trioxide.

• Authors: Kazuhiro Yago, Maki Aono, Hideto Shimada
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 51 Issue 4 Pg. 286-90 (Apr 2010) ISSN: 0485-1439 [Print] Japan
• PMID: 20467227 (Publication Type: Journal Article)

Chemical References

• Aminoglycosides
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Gemtuzumab

Topics

• Aged
• Aminoglycosides (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (administration & dosage)
• Drug Administration Schedule
• Female
• Gemtuzumab
• Humans
• Leukemia, Promyelocytic, Acute (drug therapy, genetics)
• Recurrence
• Remission Induction
• Time Factors
• Treatment Outcome